# Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients

> **NCT01393795** · PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 11 (actual)

## Conditions studied

- Pulmonary Hypertension
- Pain

## Interventions

- **DRUG:** Qutenza
- **DRUG:** Tegaderm

## Key facts

- **NCT ID:** NCT01393795
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01393795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01393795, "Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01393795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*